VCEL
Vericel CorpCompany Information
- Company Name
- Vericel Corp
- CIK
- CIK0000887359
- Category
- Large accelerated filer
- Ticker: Exchange
- VCEL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VCEL
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 205,379
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 53,752,701
- Shares outstanding
- 51,075,000
- Ownership
- 105.24%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- -10.35%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 125 | 109 | 100 | 100 | 81 | 73 | 75 | 54 | 50 | 63 | 69 | 60 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 6 | 11 | 17 | 26 | 8 | 18 | 23 | ||||||
| Short Term Investments | 37 | 36 | 37 | 35 | 36 | 39 | 42 | 48 | 52 | 48 | 40 | 45 | ||||||
| Accounts Receivable Net Current | 76 | 72 | 85 | 60 | 64 | 53 | 61 | 48 | 48 | 50 | 58 | 40 | ||||||
| Inventory Net | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 16 | 15 | 14 | 13 | 13 | ||||||
| Other Assets Current | 8 | 8 | 8 | 8 | 7 | 9 | 7 | 8 | 6 | 8 | 7 | 5 | ||||||
| Assets Current | 265 | 244 | 247 | 222 | 205 | 198 | 213 | 191 | 197 | 190 | 206 | 186 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 106 | 107 | 108 | 109 | 110 | 108 | 103 | 88 | 73 | 56 | 42 | 30 | ||||||
| Finite Lived Intangible Assets Net | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | ||||||
| Operating Lease Right Of Use Asset | 62 | 63 | 65 | 66 | 67 | 69 | 70 | 72 | 73 | 74 | 73 | 73 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 65 | 65 | 61 | 50 | 47 | 43 | 40 | 33 | 26 | 29 | 25 | 20 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 503 | 486 | 488 | 453 | 436 | 425 | 433 | 390 | 377 | 357 | 354 | 318 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 21 | 19 | 16 | 15 | 13 | 17 | 24 | 21 | 25 | 19 | 22 | 15 | ||||||
| Accrued Liabilities Current | 18 | 14 | 19 | 16 | 14 | 11 | 17 | 14 | 13 | 11 | 17 | 14 | ||||||
| Operating Lease Liability Current | 14 | 14 | 14 | 14 | 14 | 11 | 9 | 6 | 6 | 6 | 6 | 7 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 53 | 47 | 49 | 46 | 41 | 39 | 50 | 41 | 44 | 36 | 46 | 36 | ||||||
| Operating Lease Liability Noncurrent | 78 | 80 | 82 | 84 | 86 | 88 | 90 | 91 | 90 | 86 | 82 | 78 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 133 | 129 | 133 | 131 | 129 | 129 | 141 | 133 | 134 | 123 | 128 | 114 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 751 | 739 | 731 | 721 | 711 | 699 | 685 | 670 | 655 | 641 | 629 | 621 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -380 | -383 | -376 | -400 | -405 | -404 | -393 | -413 | -412 | -407 | -403 | -416 | ||||||
| Stockholders Equity | 370 | 356 | 355 | 322 | 307 | 295 | 292 | 257 | 243 | 234 | 226 | 204 | ||||||
| Liabilities And Stockholders Equity | 503 | 486 | 488 | 453 | 436 | 425 | 433 | 390 | 377 | 357 | 354 | 318 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||||
| Common Stock Shares Issued | 51 | 51 | 51 | 51 | 50 | 50 | 50 | 49 | 49 | 48 | 48 | 48 | ||||||
| Shares Outstanding | 51 | 51 | 51 | 51 | 50 | 50 | 50 | 49 | 49 | 48 | 48 | 48 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVericel Corp (VCEL) — SEC Financial Statements & Analysis
Vericel Corp (VCEL) is a biological products, (no diagnostic substances) company, incorporated in MI. Vericel Corp trades on Nasdaq as: VCEL. Vericel Corp (VCEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Vericel Corp carries a market cap of $2.27B, a P/E ratio of 93.82x, a P/B ratio of 6.14x, a P/S ratio of 7.42x, an enterprise value of $2.15B, and an EV/EBITDA multiple of 68.91x. On profitability, it posts a gross margin of 74.56%, an operating margin of 5.95%, a net margin of 7.91%, a Return on Equity (ROE) of 7.16%, a Return on Assets (ROA) of 5.16%, and a Return on Invested Capital (ROIC) of 7.57%. Per share, it reports EPS of $0.47, diluted EPS of $0.46, free cash flow per share of $1.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 22.95% year-over-year, net income growth of 240.80% year-over-year, and EPS growth of 236.09% year-over-year. On the balance sheet, it maintains a current ratio of 5.04x, a quick ratio of 4.69x, working capital of $212.20M, a debt-to-equity ratio of 0.36x, a debt ratio of 0.26, an interest coverage ratio of 28.49x, free cash flow of $54.11M (TTM), and net debt of $-125.36M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.27B
- P/E TTM
- 93.82x
- EPS TTM
- $0.47
- P/B TTM
- 6.14x
- ROE TTM
- 7.16%
- ROA TTM
- 5.16%
- Debt To Equity
- 0.36x
- Free Cash Flow TTM
- $54.11M
- Net Revenue TTM Growth 1Y
- 22.95%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vericel Corp in?
Vericel Corp (VCEL) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VCEL trade on?
Vericel Corp (VCEL) trades on the Nasdaq.
Where is Vericel Corp incorporated?
Vericel Corp is incorporated in MI.
When was Vericel Corp (VCEL)'s most recent SEC filing?
Vericel Corp (VCEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is VCEL's market cap?
Vericel Corp (VCEL) has a market capitalization of $2.27B as of 2026-06-30.
What is VCEL's P/E ratio?
Vericel Corp (VCEL)'s trailing twelve month P/E ratio is 93.82x as of 2026-06-30.
What is VCEL's EPS (earnings per share)?
Vericel Corp (VCEL)'s trailing twelve month EPS is $0.47 as of 2026-06-30.
What is VCEL's ROE (return on equity)?
Vericel Corp (VCEL)'s trailing twelve month Return on Equity (ROE) is 7.16% as of 2026-06-30.
What is VCEL's ROA (return on assets)?
Vericel Corp (VCEL)'s trailing twelve month Return on Assets (ROA) is 5.16% as of 2026-06-30.
What is VCEL's ROIC (return on invested capital)?
Vericel Corp (VCEL)'s trailing twelve month Return on Invested Capital (ROIC) is 7.57% as of 2026-06-30.
What is VCEL's EV/EBITDA?
Vericel Corp (VCEL)'s trailing twelve month EV/EBITDA is 68.91x as of 2026-06-30.